Switching to NGS would lead to more targeted NSCLC care, but may not reduce costs
The study, based on care in Japan, found that patients would be more quickly referred for targeted therapy. Adopting next-generation sequencing (NGS) instead of sequential single gene testing (SSG) would likely result in a small increase in future costs for diagnosing and treating patients with advanced non-small cell lung cancer (NSCLC) , but the change …
Switching to NGS would lead to more targeted NSCLC care, but may not reduce costs Read More »